ERBB2 and non-small cell lung carcinoma: In conclusion, anti-HER2 antibodies, chemotherapy and immunotherapy seem to be limited-benefit therapeutic approaches for NSCLC patients with HER2 alterations, whereas ADCs (Trastuzumab deruxtecan and T-DM1) and TKIs, such as poziotinib and pyrotinib, are emerging treatment options [96].